This article summarizes key points from Dr. Bernard Leblanc’s presentation European Perspectives on Alternative Mouse Carcinogenicity Models and a distillation of questions and answers from a panel discussion following presentations on Alternative Mouse Models for Carcinogenicity Assessment at the Society of Toxicologic Pathology’s annual symposium on June 23, 2009, in Washington, DC.
CHMP Safety Working Party (2004). CHMP SWP conclusions and recommendations on the use of genetically modified animal models for carcinogenicity assessment. http://www.emea.europa.eu/pdfs/human/swp/259202en.pdf. Accessed July 2, 2009.
2.
International Conference on Harmonization.1998. Carcinogenicity: Testing for Carcinogenicity or Pharmaceuticals (ICH Topic S1B). Available at http://www.emea.europa.eu/pdfs/human/ich/029995en.pdf . Accessed July 2, 2009.
3.
van der Laan, J.W., Silva Lima, B., and Snodin, D. ( 2002). Alternative models in carcinogenicity testing-a European perspective. Toxicol Pathol30, 157-59.
